CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BRAIN Biotech AG

BNN.DE
$68MMicro Cap

Next catalyst

Phase 2Q3 2027

INS-GSH

Parkinson Disease

Get an email about BNN.DE's next catalysts

Track BRAIN Biotech (BNN.DE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline

Catalyst Timeline

3 upcoming, 0 past

Phase 2Next

INS-GSH Phase 2 Est. Readout (NOSE-PD)

Q3 2027~QINS-GSH56

Estimated primary completion for INS-GSH trial (NCT05266417) in Parkinson Disease. Topline data typically follows completion by weeks to months.

Source
Phase 2

Methylphenidate (MPH) Phase 2 Est. Readout (PRIME)

Q4 2027~QMethylphenidate (MPH)12

Estimated primary completion for Methylphenidate (MPH) trial (NCT07279740) in Alzheimer s Disease. Topline data typically follows completion by weeks to months.

Source
Phase 2

Nabiximols Phase 2 Est. Readout (ARISTOCRAT)

Q4 2027~QNabiximols122

Estimated primary completion for Nabiximols trial (NCT05629702) in Glioblastoma. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

XetraPharmaceutical Preparations🇩🇪EuropeZwingenberg280 employees
Drug Pipeline

Celecoxib

Phase 3

Depressive Disorder, Major

Nerinetide (NA-1)

Phase 3

Acute Cerebral Ischemia

Escitalopram oxalate

Phase 3

Major Depressive Disorder

Progesterone

Phase 3

Alcohol Dependence

Inhaled isoflurane administered by Sedaconda ACD-S

Phase 3

Post-Intensive Care Syndrome

Levetiracetam

Phase 2

Parkinson Disease

Vismodegib

Phase 2

Intracranial Meningioma

Nitrous Oxide

Phase 2

Obsessive-Compulsive Disorder

TN-TC11G

Phase 2

Glioblastoma

Methylphenidate (MPH)

Phase 2

Alzheimer s Disease

Minocycline

Phase 2

Spinal Cord Injuries

Guanfacine

Phase 2

Schizotypal Personality Disorder

Mifepristone

Phase 2

Major Depressive Disorder

Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir

Phase 2

Leptomeningeal Metastasis of Breast Cancer

MMFS-202-302

Phase 2

Schizophrenia

Nabiximols

Phase 2

Glioblastoma

Sildenafil

Phase 2

Hypoactive Sexual Desire Disorder

Valacyclovir HCI

Phase 2

Schizophrenia

Sertraline

Phase 2

Neurodevelopmental Disorders

Ketamine

Phase 2

Bipolar Disorder

Capecitabine

Phase 2

Brainstem Glioma

Ganaxolone

Phase 2

PTSD

Roflumilast Oral Tablet

Phase 2

Cerebrovascular Disorders

CBD

Phase 2

Alzheimer Disease

Bezafibrate

Phase 2

Bipolar Disorder

adMSC

Phase 2

Cognitive Dysfunction

HSPPC-96

Phase 2

Brain and Central Nervous System Tumors

Palmitoylethanolamide (PEA)

Phase 2

Bipolar Depression

Probucol

Phase 2

Dementia of the Alzheimer Type

Neratinib

Phase 2

Glioblastoma

Levetiracetam (LEV)

Phase 2

Hippocampal Hyperactivation

Fluoxetine Hydrochloride

Phase 2

Stroke

QBS10072S

Phase 2

Glioblastoma

Treatment as Usual (TAU)

Phase 2

Bipolar Depression

Temozolomide Oral Product

Phase 2

Glioblastoma

CC-115

Phase 2

Glioblastoma

Rett-T

Phase 2

Rett Syndrome

Testosterone

Phase 2

Hypoactive Sexual Desire Disorder

Buspirone hydrochloride

Phase 2

Hypoactive Sexual Desire Disorder

INS-GSH

Phase 2

Parkinson Disease

0.5 mgTestosterone + Buspirone

Phase 2

Hypoactive Sexual Desire Disorder

Etidronate

Phase 2

Fahr Disease

Abemaciclib

Phase 2

Meningioma

Frequently asked questions

What is in BRAIN Biotech AG's drug pipeline?→

CatalystAlert tracks 43 drug candidates in BRAIN Biotech AG's (BNN.DE) pipeline across Phase 3, Phase 2. Its lead program is Celecoxib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is BRAIN Biotech AG's next FDA catalyst?→

BRAIN Biotech AG's (BNN.DE) next tracked catalyst is a Phase 2 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track BNN.DE biotech catalysts?→

Add BNN.DE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BRAIN Biotech AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply